BioAtla, Inc.
corporate_fare Company Profile
BioAtla, Inc. (OTC:BCAB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for BCAB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 20 rated 8 or above. Recent SEC coverage for BCAB spans 10-Q, S-1, 8-K, DEF 14A.
Recent high-impact activity:
- BioAtla 10-Q: $0.6M Cash Left, Going Concern Reaffirmed, $4.9M Impairment
- BioAtla Registers 8.18M Shares for New $40M Yorkville Standby Equity Facility
- BioAtla Signs $40M Yorkville Equity Line, Replacing $15M SEPA
- BioAtla Delisting Confirmed: Nasdaq Trading Suspension Set for August 31
- BioAtla Flags Going Concern with $1.5M Cash, Pauses Enrollment
Financial Snapshot
Short Interest & Short Volume
6.22 days to coverFINRA reported short interest of 71,975 shares in BCAB as of the October 30, 2026 settlement, a 1.2% decrease from the prior period — about 6.2 days to cover at its recent average daily volume. On November 20, 2026, 23.4% of BCAB volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for BCAB, detected from its recent SEC filings.
New $40M Yorkville Standby Facility · 8.18M Shares Registered for Resale
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →